The observed increase in kidney concentrations of phosphorylated NF-κB (p-NF-κB) and beta-catenin, in both CIS-treated Gal-3 wild-type and KO mice, with significantly higher levels in Gal-3 wild-type mice compared to Gal-3 KO mice, supports the idea that the absence of Gal-3 is associated with lower concentrations of these signaling molecules. The gene discussed is NFKB1; the disease is in situ carcinoma.